Systemic toxicity and toxicokinetics study of self-assembled-micelle inhibitory RNA-targeting amphiregulin in cynomolgus monkeys following intravenous injection.

Abstract

Self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG) is a novel RNA interference-based nanoparticle for treating fibrotic diseases. The present non-clinical study investigated the potential 4-week repeated intravenous dose toxicity and toxicokinetics of SAMiRNA-AREG at dose levels of 0, 25, 50, and 100 mg/kg/day in cynomolgus monkeys. During the test period, mortality, clinical observation, body and organ weights, food consumption, ophthalmology, electrocardiography, hematology, serum chemistry, urinalysis, and gross and microscopic pathology were examined. Serum samples were collected at various time points (0, 0.1, 0.5, 1, 3, 6, 10, 24, and 48 h) after dosing on days 1 and 29 for toxicokinetic analysis. The repeated intravenous dose toxicity study revealed no treatment-related significant changes or serious toxicity compared to the vehicle control group. SAMiRNA-AREG exhibited a non-linear toxicokinetic profile, with the t_1/2 value ranging from 2.97 to 5.88 h in single dosing and from 2.44 to 4.01 h in repeated dosing. In conclusion, the no-observed-adverse-effect level for SAMiRNA-AREG was considered to be ≥ 100 mg/kg/day with C_max and AUC_last values of 650,181.0-764,279.7 μg/mL and 539,728.0-606,033.5 h ng/mL, respectively, on day 29, and no target organs were identified.